Stock 2162 KEYMED BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:16 02/05/2024 pm IST 		5-day change 1st Jan Change
36.2 HKD +6.63% Intraday chart for Keymed Biosciences Inc. +12.07% -26.27%
30/04 Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA MT
29/04 Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA
MT
Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points
MT
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Stapokibart Injection for the Treatment of Seasonal Allergic Rhinitis
CI
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study
MT
KeyMed Biosciences’ Attributable Loss Widens in 2023
MT
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Keymed Biosciences Buys Back Shares
MT
Keymed's Rhinosinusitis Treatment Achieves Primary Endpoints; Shares Rise 5%
MT
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps
CI
China Accepts New Drug Application for Keymed Biosciences' Atopic Dermatitis Injection; Shares Rise 4%
MT
Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection
CI
Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug
MT
Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901
CI
Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023
CI
Keymed Biosciences’ Profit Surges in H1
MT
Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Keymed Biosciences to Acquire 18.7% of Kangnuo Xing for 150.6 Million Yuan
MT
Keymed Presents Data on Phase 1 Study for Lymphoma, Myeloma Drug; Shares Fall 4%
MT
Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313
CI
Keymed Biosciences Completes Data Unblinding for Phase 3 Study of Eczema Treatment; Shares Rise 8%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2162 Stock
  4. News Keymed Biosciences Inc.